Jennifer Clay Cather

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

Medicine, Dermatology, Immunology +17

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

C. Paul, Jennifer Clay Cather, Melinda Gooderham et al. · British Journal of Dermatology · 2015 · 479 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

Kim Papp, Kristian Reich, C. Paul et al. · British Journal of Dermatology · 2016 · 459 citations

Medicine, Dermatology, Pharmacotherapy +13

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

Kim Papp, Jennifer Clay Cather, Les Rosoph et al. · The Lancet · 2012 · 280 citations

Medicine, Dermatology, Pharmacotherapy +6

Association of Erythrodermic Cutaneous T-Cell Lymphoma, Superantigen-Positive Staphylococcus aureus, and Oligoclonal T-Cell Receptor Vβ Gene Expansion

Clotilde M. Jackow, Jennifer Clay Cather, Vicki Hearne et al. · Blood · 1997 · 245 citations · Full text

Life Sciences, Dermatology, Immunology +14